Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC

MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.